Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound in Second Pre-Clinical Study for Non-Alcoholic Fatty Liver Disease (MarketScreener)

Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound in Second Pre-Clinical Study for Non-Alcoholic Fatty Liver Disease

Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., announces that its lead compound for non-alcoholic steatohepatitis (NASH) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM mouse model from SMC Laboratories. In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has been screening for new therapeutic uses as part of its drug repurposing strategy.

Learn more about Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound in Second Pre-Clinical Study for Non-Alcoholic Fatty Liver Disease.
X